4G Clinical's JP Kappelle speaks with ACRP about how the pace of DCT adoption is proceeding as COVID-19's biggest threats to trial operations weaken.
Most experts agree that the deployment of decentralized clinical trials (DCTs) or hybrid variants is among the tactics that are here to stay. However, there’s wide-ranging debate on how the pace of DCT adoption is proceeding as COVID-19’s biggest threats to trial operations weaken.
"Unfortunately, I’d admit we’ve taken a step back” in terms of embracing DCTs and hybrid approaches, says JP Kappelle, vice president of strategy at 4G Clinical.
While he’s a big fan and remains bullish on the overall trend, he’s observed in the past few months that many are “reverting” to defaulting to in-person trial operations rather than considering remote options.
“We aren’t back to where we were before the pandemic, but we are seeing” a dip in the enthusiasm curve, he says.